Compare Honest Company Inc (HNST) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Honest Company Inc vs 10X Genomics Inc — how do they compare? Honest Company Inc trades at $5.05 (market cap $533.20M), while 10X Genomics Inc trades at $80.88 (market cap $10.07B). The key difference: 10X Genomics Inc is far larger — about 18.9× Honest Company Inc's market cap, and 10X Genomics Inc is more actively traded (5,657,286 versus 1,990,155). Which is the better fit depends on your goals — on Pluang, investors hold Honest Company Inc for 39 Days and 10X Genomics Inc for 91 Days on average.
| HNST | TXG | |
|---|---|---|
Market Cap | $533.20M | $10.07B |
Volume | 1,990,155 | 5,657,286 |
Sector | Consumer Staples | Health |
52-Week High | $5.95 | $97.74 |
52-Week Low | $2.10 | $11.48 |
Typical Hold Time | 39 Days | 91 Days |
Enterprise Value | $436.81M | $9.59B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HNST trades at $5.07, up 2.84% today, but remains in a bearish technical trend. The company shows mixed fundamentals with declining revenue to $371.32M in 2025 and a net loss of -$15.69M, though Q2 2026 earnings beat expectations. Analyst sentiment is cautious with a $5.30 consensus target, while institutional buying from BlackRock and Deutsche Bank provides some support.
The outlook remains challenging with persistent profitability issues and competitive pressures. While strategic exits show early promise and cash flow improved to $14.15M in 2025, investors face risks from margin compression and uncertain growth trajectory. The stock trades at premium valuations despite negative returns, requiring careful risk assessment.
TXG trades at $80.65, up 5.98% on the day, showing strong recent momentum despite a bearish technical signal. The company reported revenue of $642.82M for 2025 with a gross margin of 70.03%, but remains unprofitable with a net loss of $43.54M. Recent news highlights the launch of the Atera spatial biology platform and a patent victory, signaling innovation and competitive strength. Analyst consensus is mixed with a $74.30 price target below the current price, indicating caution on valuation.
The outlook for TXG hinges on commercial execution of new products like Atera to drive revenue growth and a path to profitability. Investment opportunity lies in its leading technology platform and expanding market demand in genomics. Key risks include persistent losses, high valuation multiples, and competitive pressures in the life sciences tools sector. The stock's recent rally faces a test near technical resistance at $81.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Honest Company Inc
The Honest Co Inc is a consumer products company. It offers eco-friendly diapers and a natural line of bath, skincare, home cleaning, and organic nutritional supplement products and other products.
Read more on HNST →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
